arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

AbbVie Inc.

ABBV
$265.64 ▲ +0.34 (+0.13%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
16 Visible periods
34 Metrics
Peer-ranked Benchmarks
Price Chart
59
Health
Fair
Neutral
auto_awesome

Analytical Summary

AbbVie Inc. demonstrates solid fundamentals with strength in Debt to Equity. However, watch Return on Common Equity (%) which shows concerning trends. Consider comparing against peers in the Healthcare sector before making investment decisions.

Market Cap $469.9B
Dividend Yield 2.50%
Revenue Growth 8.6% ↗
Op. Margin 24.6% ↗
ROIC 15.8% ↘
FCF / Share $10.07 →
Trailing P/E 112.1x
Price / Book —
FCF Yield 3.8%
Debt / Equity -20.49
info Valuation on last close. End-of-day price, Sep 23, 2026.

16-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$61.16B
↑ +8.6% —
Net Income Profit after all expenses
$4.23B
↓ -1.2% —
Operating Margin Operating profit as % of sales
24.6%
↑ +52.0% 81th
FCF / Share Free cash flow per share
$10.07
— -0.1% —
Long-Term Debt Long-term obligations
$64.50B
↑ +8.9% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
  • Operating Margin (%)Operating Margin (%) is in the top quartile
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↓
76
Returns
6
Financial Health ↓
87
Cash Quality ↑
94

Dividend History

Dividend / share · sourced from SEC filings
$6.65 Latest / share
+5.7% YoY
+12.9% 12-yr CAGR

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 16 years · 60 quarters